{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:38:25Z","timestamp":1762843105503,"version":"build-2065373602"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"vor","delay-in-days":31,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009432","name":"Government Council on Grants, Russian Federation","doi-asserted-by":"publisher","award":["15.34.3.2017","15.64.785.2017"],"award-info":[{"award-number":["15.34.3.2017","15.64.785.2017"]}],"id":[{"id":"10.13039\/501100009432","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.ctarc.2022.100529","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T02:36:26Z","timestamp":1643855786000},"page":"100529","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Hypothesis for the development of immune-related adverse events in immune checkpoint inhibitors therapy"],"prefix":"10.1016","volume":"31","author":[{"given":"Rashida","family":"Orlova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Zhukova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Malkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yehuda","family":"Shoenfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2022.100529_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ctarc.2022.100529_bib0002","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.thorsurg.2020.01.001","article-title":"Adjuvant and neoadjuvant immunotherapy in non-small cell lung cancer","volume":"30","author":"Broderick","year":"2020","journal-title":"Thorac. Surg. Clin."},{"key":"10.1016\/j.ctarc.2022.100529_bib0003","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2217\/fon-2020-0986","article-title":"Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy","volume":"17","author":"Rizzo","year":"2021","journal-title":"Future Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2022.100529_bib0004","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med."},{"key":"10.1016\/j.ctarc.2022.100529_bib0005","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1136\/bmj.k793","article-title":"Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis","volume":"360","author":"Baxi","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.ctarc.2022.100529_bib0006","doi-asserted-by":"crossref","first-page":"vi369","DOI":"10.1093\/annonc\/mdw378.31","article-title":"A meta-analysis of immune-related adverse events (irAE) of immune checkpoint inhibitors (ICI) from cancer clinical trials","volume":"27","author":"El","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2022.100529_bib0007","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1080\/14740338.2020.1811226","article-title":"Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis","volume":"19","author":"Massari","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"issue":"Suppl 7","key":"10.1016\/j.ctarc.2022.100529_bib0008","doi-asserted-by":"crossref","first-page":"vii59","DOI":"10.1093\/rheumatology\/kez308","article-title":"Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors","volume":"58","author":"Weinmann","year":"2019","journal-title":"Rheumatology"},{"issue":"10","key":"10.1016\/j.ctarc.2022.100529_bib0009","first-page":"1","article-title":"Classical examples of the concept of the ASIA syndrome","volume":"10","author":"Boba","year":"2020","journal-title":"Biomolecules"},{"issue":"22","key":"10.1016\/j.ctarc.2022.100529_bib0010","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1182\/blood-2011-11-388918","article-title":"Basis of CTLA-4 function in regulatory and conventional CD4+ T cells","volume":"119","author":"Tai","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2022.100529_bib0011","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2022.100529_bib0012","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations","volume":"8","author":"Seidel","year":"2018","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.ctarc.2022.100529_bib0013","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1002\/eji.200737583","article-title":"Programmed cell death\u20041 (PD-1) and its ligand PD-L1 are required for allograft tolerance","volume":"37","author":"Wang","year":"2007","journal-title":"Eur. J. Immunol."},{"issue":"6","key":"10.1016\/j.ctarc.2022.100529_bib0014","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1084\/jem.20112741","article-title":"Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2","volume":"209","author":"Yokosuka","year":"2012","journal-title":"J. Exp. Med."},{"issue":"6332","key":"10.1016\/j.ctarc.2022.100529_bib0015","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science (80-)"},{"issue":"1","key":"10.1016\/j.ctarc.2022.100529_bib0016","first-page":"1","article-title":"Targeting inflammasome\/IL-1 pathways for cancer immunotherapy","volume":"6","author":"Guo","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ctarc.2022.100529_bib0017","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1053\/j.seminoncol.2017.06.002","article-title":"A molecular and preclinical comparison of the PD-1\u2013targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab","volume":"44","author":"Fessas","year":"2017","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ctarc.2022.100529_bib0018","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/cr.2016.102","article-title":"Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy","volume":"27","author":"Liu","year":"2017","journal-title":"Cell Res."},{"issue":"3","key":"10.1016\/j.ctarc.2022.100529_bib0019","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1615\/CritRevImmunol.2018025204","article-title":"Avelumab: a novel anti-Pd-l1 agent in the treatment of merkel cell carcinoma and urothelial cell carcinoma","volume":"38","author":"Teets","year":"2018","journal-title":"Crit. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.ctarc.2022.100529_bib0020","first-page":"98","article-title":"CTLA-4 and PD-1 pathways similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am. J. Clin. Oncol. Cancer Clin. Trials"},{"issue":"9","key":"10.1016\/j.ctarc.2022.100529_bib0021","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1111\/1759-7714.13541","article-title":"Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients","volume":"11","author":"Song","year":"2020","journal-title":"Thorac. Cancer"},{"issue":"3","key":"10.1016\/j.ctarc.2022.100529_bib0022","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s10620-020-06103-x","article-title":"Gut microbiome and immune checkpoint inhibitor-induced enterocolitis","volume":"65","author":"Abu-Sbeih","year":"2020","journal-title":"Dig. Dis. Sci."},{"issue":"6","key":"10.1016\/j.ctarc.2022.100529_bib0023","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","article-title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab","volume":"28","author":"Chaput","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2022.100529_bib0024","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10391","article-title":"Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis","volume":"7","author":"Dubin","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ctarc.2022.100529_bib0025","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2018.11.009","article-title":"Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors","volume":"107","author":"Hasan Ali","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"MAR","key":"10.1016\/j.ctarc.2022.100529_bib0026","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fonc.2018.00080","article-title":"Immune dysregulation in cancer patients undergoing immune checkpoint inhibitor treatment and potential predictive strategies for future clinical practice","volume":"0","author":"Anderson","year":"2018","journal-title":"Front. Oncol."},{"issue":"MAR","key":"10.1016\/j.ctarc.2022.100529_bib0027","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3389\/fmicb.2018.00432","article-title":"Intestinal Microbiota Influences non-intestinal related autoimmune diseases","volume":"9","author":"Opazo","year":"2018","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ctarc.2022.100529_bib0028","first-page":"S44","article-title":"Cutaneous manifestation of gastrointestinal disease","volume":"7","author":"Rahvar","year":"2016","journal-title":"J. Gastrointest. Oncol."},{"issue":"8","key":"10.1016\/j.ctarc.2022.100529_bib0029","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1097\/PAS.0000000000000653","article-title":"Comprehensive immunohistochemical study of programmed cell death ligand 1 (PD-L1): analysis in 5536 cases revealed consistent expression in trophoblastic tumors","volume":"40","author":"Inaguma","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"issue":"7","key":"10.1016\/j.ctarc.2022.100529_bib0030","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1089\/thy.2016.0562","article-title":"Clinical features of nivolumab-induced thyroiditis: a case series study","volume":"27","author":"Yamauchi","year":"2017","journal-title":"Thyroid"},{"issue":"2","key":"10.1016\/j.ctarc.2022.100529_bib0031","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1507\/endocrj.EJ20-0371","article-title":"Distinct clinical features and prognosis between persistent and temporary thyroid dysfunctions by immune-checkpoint inhibitors","volume":"68","author":"Inaba","year":"2021","journal-title":"Endocr. J."},{"issue":"3","key":"10.1016\/j.ctarc.2022.100529_bib0032","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/rheumatology\/key358","article-title":"Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis","volume":"58","author":"Cappelli","year":"2019","journal-title":"Rheumatology"},{"issue":"8","key":"10.1016\/j.ctarc.2022.100529_bib0033","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: Insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Bluestone","year":"2018","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.ctarc.2022.100529_bib0034","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1002\/acn3.51213","article-title":"HLA-B27 association of autoimmune encephalitis induced by PD-L1 inhibitor","volume":"7","author":"Chang","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.ctarc.2022.100529_bib0035","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejca.2020.02.049","article-title":"Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor\u2013induced secondary adrenal insufficiency","volume":"130","author":"Yano","year":"2020","journal-title":"Eur. J. Cancer"},{"issue":"15","key":"10.1016\/j.ctarc.2022.100529_bib0036","article-title":"Incidence and clinical pattern of immune related adverse effects (irAE) due to immune checkpoint inhibitors (ICI)","volume":"37","author":"Thapa","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2022.100529_bib0037","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0821-8","article-title":"Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study","volume":"7","author":"Manson","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ctarc.2022.100529_bib0038","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp.2010.224105","article-title":"Which antibody and which cancer in which paraneoplastic syndromes?","author":"Gozzard","year":"2010","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.ctarc.2022.100529_bib0039","doi-asserted-by":"crossref","DOI":"10.1053\/j.semdp.2019.01.001","article-title":"Cutaneous paraneoplastic syndromes","author":"Wick","year":"2019","journal-title":"Semin. Diagn. Pathol."},{"issue":"6","key":"10.1016\/j.ctarc.2022.100529_bib0040","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21062178","article-title":"Paraneoplastic dermatoses: a brief general review and an extensive analysis of paraneoplastic pemphigus and paraneoplastic dermatomyositis","volume":"21","author":"Didona","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.ctarc.2022.100529_bib0041","article-title":"Paraneoplastic rheumatic syndromes","volume":"14","author":"Fam","year":"2000","journal-title":"Bailliere's Best Pract. Res. Clin. Rheumatol."},{"issue":"1","key":"10.1016\/j.ctarc.2022.100529_bib0042","article-title":"Paraneoplastic rheumatic disorders","volume":"27","author":"Omer","year":"2012","journal-title":"Turk. J. Rheumatol."},{"issue":"5","key":"10.1016\/j.ctarc.2022.100529_bib0043","doi-asserted-by":"crossref","DOI":"10.1067\/j.cpsurg.2010.01.003","article-title":"Cutaneous manifestations of internal malignancy","volume":"47","author":"Ehst","year":"2010","journal-title":"Curr. Probl. Surg."},{"year":"2020","series-title":"Associations Between HLA and Autoimmune Neurological Diseases With Autoantibodies","author":"Mu\u00f1iz-Castrillo","key":"10.1016\/j.ctarc.2022.100529_bib0044"},{"issue":"2","key":"10.1016\/j.ctarc.2022.100529_bib0045","first-page":"73","article-title":"Cutaneous manifestations of internal malignancy","volume":"59","author":"Thiers","year":"2009","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.ctarc.2022.100529_bib0046","doi-asserted-by":"crossref","DOI":"10.1007\/s12026-016-8817-7","article-title":"HLA-DRB1 the notorious gene in the mosaic of autoimmunity","volume":"65","author":"Arango","year":"2017","journal-title":"Immunol. Res."},{"issue":"JUN","key":"10.1016\/j.ctarc.2022.100529_bib0047","article-title":"Probiotics lactobacillus reuteri abrogates immune checkpoint blockade-associated colitis by inhibiting group 3 innate lymphoid cells","volume":"10","author":"Wang","year":"2019","journal-title":"Front. Immunol."},{"issue":"15_suppl","key":"10.1016\/j.ctarc.2022.100529_bib0048","doi-asserted-by":"crossref","first-page":"e15068","DOI":"10.1200\/JCO.2018.36.15_suppl.e15068","article-title":"Impact of comorbidity on immune checkpoint blockade tolerance across tumor types","volume":"36","author":"Clark-Garvey","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2022.100529_bib0049","doi-asserted-by":"crossref","first-page":"e922576","DOI":"10.12659\/MSM.922576","article-title":"Effect of comorbidity on outcomes of patients with advanced non-small cell lung cancer undergoing anti-PD1 immunotherapy","volume":"26","author":"Zeng","year":"2020","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.ctarc.2022.100529_bib0050","first-page":"55","article-title":"Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association?","volume":"17","author":"Hussain","year":"2021"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246829422200020X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246829422200020X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:34:20Z","timestamp":1762842860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S246829422200020X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":50,"alternative-id":["S246829422200020X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2022.100529","relation":{},"ISSN":["2468-2942"],"issn-type":[{"type":"print","value":"2468-2942"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypothesis for the development of immune-related adverse events in immune checkpoint inhibitors therapy","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2022.100529","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100529"}}